Treace Medical Concepts (TMCI) Equity Average (2020 - 2026)

Treace Medical Concepts has reported Equity Average for 7 years, with the latest figure at $82.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 24.61% year-over-year to $82.3 million; the trailing twelve-month figure through Mar 2026 stood at $82.3 million (down 24.61% YoY), and the FY2025 full-year result was $100.1 million, down 20.18% from the prior year.
• Equity Average for Q1 2026 stood at $82.3 million, down from $88.3 million in the prior quarter.
• The five-year high for Equity Average was $153.8 million in Q2 2023, with the low at $61.4 million in Q4 2022.
• Historically, Equity Average has averaged $105.0 million across 5 years, with a median of $108.5 million in 2024.
• The largest YoY upside for Equity Average was 195433.7% in 2022 against a maximum downside of 35.56% in 2022.
• Treace Medical Concepts' Equity Average stood at $61.4 million in 2022, then jumped by 124.72% to $137.9 million in 2023, then retreated by 21.03% to $108.9 million in 2024, then retreated by 18.95% to $88.3 million in 2025, then decreased by 6.8% to $82.3 million in 2026.
• The last three Equity Average figures came in at $82.3 million (Q1 2026), $88.3 million (Q4 2025), and $93.4 million (Q3 2025), per Business Quant data.